In parallel with the increase in the bioavailability of aluminum, there has been a widespread increase in aluminum exposure in humans, primarily through vaccination. Aluminum salts in vaccines act as adjuvants – substances that enhance the immune response and improve vaccine efficacy. In 1926, the first aluminum-based was discovered by Alexander Glenny. Aluminum salts are widely used in pharmaceuticals due to their ability to adsorb antigens through weak interactions while preserving their structural integrity. The mechanisms of action of aluminum adjuvants include – “Depot effect”, “Pro-phagocytic effect” and “NLRP3 inflammasome”. A correlation has been found between cases of autism and “Gulf War Syndrome” and the presence of aluminum adjuvants in vaccines. The WHO issues a positive assessment of the use of aluminum adjuvants in vaccines, recognizing their benefits in the fight to protect public health.
Milchev et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: